Literature DB >> 810132

Canine erythrocyte pyruvate kinase. I. Properties of the normal enzyme.

J A Black, C J Chern, M B Rittenberg.   

Abstract

We have compared the kinetic, immunological, and electrophoretic properties of human and canine erythrocyte pyruvate kinase. Both enzymes are allosteric and subject to positive and negative regulation. The allosteric properties of the canine enzyme are more pronounced than those of the human enzyme; however, the properties of both enzymes are consistent with a regulatory function in the glycolytic pathway of their respective erythrocytes. Antiserum against the human enzyme gives precipitin lines of partial identity between the human and canine enzymes on immunodiffusion. The anti-human serum inactivates the enzymatic activity of both enzymes, although it is more effective against the human enzyme than the canine. The two enzymes have slightly different mobilities on starch gel electrophoresis. While we have demonstrated differences between erythrocyte pyruvate kinase from dogs and that from humans, we conclude that the enzymes are sufficiently similar in properties and function to allow use of the dog as a model for human erythrocyte pyruvate kinase deficiency.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 810132     DOI: 10.1007/BF00485818

Source DB:  PubMed          Journal:  Biochem Genet        ISSN: 0006-2928            Impact factor:   1.890


  10 in total

1.  PRODUCTION OF ANTIBODIES TO DENATURED DEOXYRIBONUCLEIC ACID (DNA).

Authors:  O J PLESCIA; W BRAUN; N C PALCZUK
Journal:  Proc Natl Acad Sci U S A       Date:  1964-08       Impact factor: 11.205

2.  Method for the detection of pyruvate kinase, aldolase, and other pyridine nucleotide linked enzyme activities after electrophoresis.

Authors:  W A Susor; W J Rutter
Journal:  Anal Biochem       Date:  1971-09       Impact factor: 3.365

3.  A comparative study on the phosphoglyceric acid cycle in mammalian erythrocytes.

Authors:  D R Harkness; J Ponce; V Grayson
Journal:  Comp Biochem Physiol       Date:  1969-01

4.  Effect of oxygen tension on glycolysis in human erythrocytes.

Authors:  N Hamasaki; T Asakura; S Minakami
Journal:  J Biochem       Date:  1970-08       Impact factor: 3.387

5.  Activation and inhibition of human erythrocyte pyruvate kinase by organic phosphates, amino acids, peptides and anions.

Authors:  J A Black; M H Henderson
Journal:  Biochim Biophys Acta       Date:  1972-09-19

6.  Human pyruvate kinases. Role of the divalent cation in the catalytic mechanism of the red cell enzyme.

Authors:  H A Leonard
Journal:  Biochemistry       Date:  1972-11-07       Impact factor: 3.162

7.  Conformational differences in the active sites of muscle and erythrocyte pyruvate kinase.

Authors:  K W Jacobson; J A Black
Journal:  J Biol Chem       Date:  1971-09-10       Impact factor: 5.157

8.  Purification of human erythrocyte pyruvate kinase.

Authors:  C J Chern; M B Rittenberg; J A Black
Journal:  J Biol Chem       Date:  1972-11-25       Impact factor: 5.157

9.  [Erythrocyte isolation from blood with cotton].

Authors:  D Busch; K Pelz
Journal:  Klin Wochenschr       Date:  1966-08-15

10.  Congenital hemolytic anemia in the Basenji dog due to erythrocyte pyruvate kinase deficiency.

Authors:  G P Searcy; D R Miller; J B Tasker
Journal:  Can J Comp Med       Date:  1971-01
  10 in total
  3 in total

1.  Postnatal changes in canine erythrocyte pyruvate kinase isozymes.

Authors:  P A Mueggler; S Carpenter; J A Black
Journal:  Biochem Genet       Date:  1983-08       Impact factor: 1.890

2.  Canine erythrocyte pyruvate kinase. II. Properties of abnormal enzyme associated with hemolytic anemia in the Basenji dog.

Authors:  R J Standerfer; M B Rittenberg; C J Chern; J W Templeton; J A Black
Journal:  Biochem Genet       Date:  1975-06       Impact factor: 1.890

3.  Hemolytic anemia due to pyruvate kinase deficiency: characterization of the enzymatic activity from eight patients.

Authors:  J A Black; M B Rittenberg; R H Bigley; R D Koler
Journal:  Am J Hum Genet       Date:  1979-05       Impact factor: 11.025

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.